UK pharma deluged with trial data complaintsA new tactic in the battle to force pharma to disclose trial data has been revealed – a Share XUK pharma deluged with trial data complaintshttps://pharmaphorum.com/news/uk-pharma-deluged-with-trial-data-complaints/
Amgen cholesterol drug hits trial targetA new treatment for patients with extremely high cholesterol levels has hit its primary endpoint – but Amgen Share XAmgen cholesterol drug hits trial targethttps://pharmaphorum.com/news/amgen-cholesterol-drug-hits-trial-target/
NICE recommends Boehringer’s lung cancer drug GiotrifNICE has recommended Giotrif (afatinib), Boehringer Ingelheim’s treatment for non-small-cell lung cancer (NSCLC). The drug joins the competition Share XNICE recommends Boehringer’s lung cancer drug Giotrifhttps://pharmaphorum.com/news/nice-recommends-boehringer-s-lung-cancer-drug-giotrif/
Fast-track for Edison’s ataxia drugA new treatment for the rare disease Friedreich’s ataxia has been given ‘fast track’ status by the FDA. Share XFast-track for Edison’s ataxia drughttps://pharmaphorum.com/news/fast-track-for-edison-s-ataxia-drug/
AstraZeneca now led by science, not commercial milestones, says R&D headAstraZeneca has turned its back on a commercially-led approach in favour of a ‘science first’ strategy, according to Share XAstraZeneca now led by science, not commercial milestones, says R&D headhttps://pharmaphorum.com/news/astrazeneca-now-led-by-science-not-commercial-milestones-says-r-d-head/
Early access scheme unveiled in UKThe UK government has unveiled new scheme which will give patients with life threatening or seriously debilitating conditions Share XEarly access scheme unveiled in UKhttps://pharmaphorum.com/news/early-access-scheme-unveiled-in-uk/
Celebrex ruling could cost Pfizer billionsA US court has overturned a patent on Pfizer’s top-selling pain drug Celebrex, a surprise ruling which could Share XCelebrex ruling could cost Pfizer billionshttps://pharmaphorum.com/news/celebrex-ruling-could-cost-pfizer-billions/
Nexavar fails in liver cancerBayer and Onyx’s cancer treatment Nexavar has failed to show benefit in preventing the return of liver cancer Share XNexavar fails in liver cancerhttps://pharmaphorum.com/news/nexavar-fails-in-liver-cancer/
UCB and Sanofi to collaborate in immune diseasesUCB and Sanofi have unveiled a scientific and strategic collaboration to discover and develop novel treatments for immune-mediated Share XUCB and Sanofi to collaborate in immune diseaseshttps://pharmaphorum.com/news/ucb-and-sanofi-to-collaborate-in-immune-diseases/
